NCT02452775终止1 期
A Randomized Pilot Trial to Test the Addition of Montanide and Polyiclc to Autologous Oxidized Tumor Cell Lysate Vaccine in Combination With Gmcsf in Primary Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
适应症
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 3
- 试验地点
- 2
- 主要终点
- Numbers of Adverse Events
研究概览
简要总结
This is a randomized pilot trial to test the addition of 2 investigational agents, Montanide and poly-ICLC (a TLR3 agonist) to a backbone of autologous oxidized tumor cell lysate vaccine (OC-L) administered with GMCSF in subjects with primary epithelial ovarian, fallopian tube, or primary peritoneal cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Subject has primary ovarian (including low malignant potential), fallopian tube, or primary peritoneal cancer FIGO stage III or IV defined surgically at the completion of initial abdominal surgery.
- •Subject has had cytoreductive surgery and has completed first line platinum based chemotherapy in an adjuvant or neo-adjuvant setting as part of standard of care treatment.
- •Subject has no evidence of disease based on radiographical imaging
- •Subject has appropriate tissue available from the cytoreductive surgery tumor lysate preparation.
- •Lysate must meet release criteria.
- •Subject is 18 years of age or older.
- •Subject has an ECOG performance status of ≤
- •Subject understood and signed the study specific informed consent.
- •Subjects screened between 1 to 12 weeks after last cycle of chemotherapy.
- •Subjects screened any time after completed last cycle of chemotherapy till progression or first recurrence of the disease.
- •Subject has had at least 4 weeks of postoperative recovery from surgery prior to enrollment to ensure complete wound healing.
- •Subjects who screen fails can be re-enrolled if the causation of the screen fail has been corrected.
排除标准
- •Subject for whom tumor lysate does not meet release criteria
- •Subject has a positive serum Yo antibody (Does not need to be repeated if performed in the past)
- •Subject has a chronic or acute hepatitis C infection. Subject with an old infection that has cleared may be included.
- •Subject has a chronic or acute hepatitis B infection. Subject with an old infection that has cleared may be included.
- •Subject has positive test result at the screening visit for one or more of the following:
- •Anti-HIV 1 Antibody (α-HIV-1)
- •Subject requires or is likely to require more than a two-week course of corticosteroids for intercurrent illness. Subject must complete the course of corticosteroids 2 weeks before screening to meet eligibility.
- •Subject has renal insufficiency as defined by a serum creatinine > 2.2 mg/dl or BUN > 40 mg/dl. Note: If creatinine is greater than 1.5 x ULN, creatinine clearance must be greater than 60ml/min.
- •Subject has proteinuria > 3.5 gm over 24 hrs are not eligible for the study
- •Subject with liver failure as defined by a serum total bilirubin > 2.0 and/or serum transaminases > 3X the upper limits of normal.
- •Subject has hematopoietic failure at baseline as defined by one of the following:
- •Platelets < 100,000/ mm3
- •WBC < 2,500/mm3
- •Absolute Neutrophil Count (ANC) < 1,000/mm3
- •Absolute lymphocyte count < 200/ mm3
- •Hematocrit < 30%
- •Subject has any acute infection that requires specific therapy. Acute therapy must have been completed within seven days prior to study enrollment.
- •Subject has a serious, non-healing wound, ulcer, or bone fracture.
- •Subject has a clinically significant cardiovascular disease including:
- •Uncontrolled hypertension;
- •Myocardial infarction or unstable angina within 6 months prior to enrollment
- •New York Heart Association (NYHA) Grade II or greater congestive heart failure
- •Subject has a grade II or greater peripheral vascular disease.
- •Subject has a clinically significant peripheral artery disease, e.g., those with claudication, within 6 months.
- •Subject has any underlying conditions, which would contraindicate therapy with study treatment
- •Subject has organ allografts.
- •Subject is receiving medication(s) that might affect immune function. Use of H2 antagonists are prohibited as are all antihistamines five days before and five days after each injection of study vaccine. However, NSAIDS including COX-2 inhibitors, acetaminophen or aspirin are permitted.
结局指标
主要结局
Numbers of Adverse Events
时间窗: 3.5 years
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
终止
4 期
Pilot Study of Nicotine Nasal Spray and Varenicline on Smoking in Methadone-Maintained PatientsCigarette SmokingMethadone MaintenanceNCT02147132University of Cincinnati7
进行中（未招募）
2 期
Combination Immunotherapy in Colorectal CancerColorectal NeoplasmsNCT05571293Weill Medical College of Cornell University26
已完成
不适用
Natural Versus Synthetic Vitamin B Complexes in HumanHealthyThiamine and Niacin Deficiency StatesPyridoxine DeficiencyFolic Acid Deficiency Anemia, DietaryVitamin B 12 DeficiencyPolyphenolsOxidative StressMetabolic Disorder HomocystineDefect PeroxidaseNCT03444155Medical University of Graz30
撤回
1 期
Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian CancerPlatinum-Refractory Fallopian Tube CarcinomaPlatinum-Refractory Ovarian CarcinomaPlatinum-Refractory Primary Peritoneal CarcinomaRecurrent Fallopian Tube AdenocarcinomaRecurrent Fallopian Tube CarcinosarcomaRecurrent Fallopian Tube Clear Cell AdenocarcinomaRecurrent Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Fallopian Tube Undifferentiated CarcinomaRecurrent High Grade Endometrioid AdenocarcinomaRecurrent Ovarian AdenocarcinomaRecurrent Ovarian CarcinosarcomaRecurrent Ovarian Clear Cell AdenocarcinomaRecurrent Ovarian High Grade Serous AdenocarcinomaRecurrent Ovarian Seromucinous CarcinomaRecurrent Ovarian Undifferentiated CarcinomaRecurrent Platinum-Resistant Fallopian Tube CarcinomaRecurrent Platinum-Resistant Ovarian CarcinomaRecurrent Platinum-Resistant Primary Peritoneal CarcinomaRecurrent Primary Peritoneal AdenocarcinomaRecurrent Primary Peritoneal CarcinosarcomaRecurrent Primary Peritoneal Clear Cell AdenocarcinomaRecurrent Primary Peritoneal High Grade Serous AdenocarcinomaRecurrent Primary Peritoneal Undifferentiated CarcinomaNCT06393751National Cancer Institute (NCI)127
招募中
2 期
Ketamine & Crisis Response Plan for Suicidal Ideation in the EDSuicideNCT05696691The University of Texas Health Science Center at San Antonio24